Correlation of CK5/6 and Ki67 expression with molecular pathological features of breast cancer

doi:10.3877/cma. j. issn.1674-0807.2015.06.007

Abstract

Abstract:

Objective

To study the expression of cytokeratin 5/6 (CK5/6) and Ki67 in breast cancer and clinical significance.

Methods

The clinical data of 109 breast cancer patients treated with modified radical mastectomy in the First Affiliated Hospital of Henan University of Science and Technology from February 2011 to July 2014 were retrospectively collected. The expressions of CK5/6 and Ki67 in breast cancer tissues were detected by immunohistochemical staining, and their association with molecular pathological features of breast cancer was analyzed. Numeration data was processed using χ² test or Fisher's exact test, correlation analysis was performed using Spearman method, and Logistic regression was used for analyzing the independent factors in CK5/6 expression.

Results

The positive rates of CK5/6 and Ki67 expression in breast cancer tissue were 22.02% (24/109) and 62.04% (67/108, one case was not detected) respectively. The positive rate of CK5/6 expression was 62.2% (23/37) in triple negative breast cancer (TNBC), significantly higher than that in non-TNBC (χ² =41.708, P＜0.001); while the expression of Ki67 presented no statistical difference in different molecular subtypes of breast cancer(χ² = 0.147,P ＜0.001). CK5/6 expression was negatively correlated with ER, PR, and E-cadherin expression in breast cancer (r=-0.505, -0.417, -0.239,all P ＜0.050). Moreover, the deficiency of ER expression was an independent factor influencing CK5/6 expression(OR=0.099,95% CI=0.023-0.424). Ki67 expression was not correlated with other molecular markers including ER, PR, HER-2 and E-cadherin. The expression of E-cadherin in basal-like breast cancer (BLBC)was significantly lower than that in non-BLBC (χ²=6.669,P=0.010). In TNBC, the expressions of CK5/6 and Ki67 were positively associated with Ki67 and histological grade (r=0.354, P=0.043).

Conclusion

The malignant biological features of invasion and metastasis in BLBC with CK5/6 positive expression may be related with E-cadherin expression deficiency, while Ki67 expression may not be a molecular marker to identify BLBC.

Key words: Breast neoplasms, Keratins, Ki-67 antigen, Molecular typing

Miao Deng, Jiangbo Liu, Qipeng Liu, Ting Zhang, Yanxiao Tian, Dengting Chen, Luqi Xing. Correlation of CK5/6 and Ki67 expression with molecular pathological features of breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2015, 09(06): 380-386.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2015.06.007

https://zhrxbzz.cma-cmc.com.cn/EN/Y2015/V09/I06/380

Figures/Tables 7

References 24

[1]	赵晓辉, 郝春芳, 王忱,等. 三阴性乳腺癌的临床病理学特征及预后分析[J/CD]. 中华乳腺病杂志:电子版, 2009,3(6):590-599.
[2]	Gazinska P, Grigoriadis A, Brown JP, et al. Comparison of basal-like triple-negative breast cancer defined by morphology,immunohistochemistry and transcriptional profiles[J]. Mod Pathol,2013,26(7):955-966.
[3]	Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature,2000,406(6797):747-752.
[4]	Adelaide J, Finetti P, Bekhouche I, et al. Integrated profiling of basal and luminal breast cancers[J]. Cancer Res,2007,67(24):11 565-11 575.
[5]	Bertucci F, Finetti P, Cervera N, et al. How basal are triplenegative breast cancers[J]. Int J Cancer, 2008, 123(1):236-240.
[6]	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours [ J]. Nature, 2012,490(7418):61-70.
[7]	Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J]. Clin Cancer Res, 2008,14(5):1368-1376.
[8]	Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013,24(9):2206-2223.
[9]	王新昭,左文述,刘琪,等. 2013 年St Gallen 乳腺癌会议国际专家共识荟萃[J]. 中华肿瘤防治杂志, 2013,20(23):1859-1864.
[10]	Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al.Ki-67 is a prognostic parameter in breast cancer patients:results of a large population-based cohort of a cancer registry[J]. Breast Cancer Res Treat,2013,139(2):539-552.
[11]	刘裔莎,魏兵,杨雯娟,等.美国癌症联合会乳腺癌分期(第七版)简介[J]. 中华病理学杂志,2010,39(11):787-790.
[12]	李纪男,马振海,徐景超,等.联合检测乳腺癌组织中CK5/6、Ki-67 表达的临床意义[J]. 中国普外基础与临床杂志,2013,20(11):1245-1249.
[13]	陈万青,郑荣寿,曾红梅,等. 2011 年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2015,24(1):1-10.
[14]	Inanc M, Ozkan M, Karaca H, et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triplenegative breast cancer[J]. Med Oncol,2014,31(1):801.
[15]	李艳艳,木扎帕尔·阿不都,孙刚,等. 267 例乳腺浸润性导管癌EGFR、CK5/6 表达分析[J]. 新疆医科大学学报,2013,36(3):316-319,324.
[16]	Pintens S, Neven P, Drijkoningen M, et al. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1[J]. J Clin Pathol,2009,62(7):624-628.
[17]	Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study[J]. Breast Cancer Res Treat,2011,126(1):185-192.
[18]	Kashiwagi S, Yashiro M, Takashima T, et al. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage Ⅱ: usefulness of prognostic markers E-cadherin and Ki67[J]. Breast Cancer Res,2011,13(6): R122.
[19]	Dong C, Wu Y, Wang Y, et al. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer[J]. Oncogene,2013,32(11):1351-1362.
[20]	Knox AJ, Scaling AL, Pinto MP, et al. Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease[J]. Breast Cancer Res, 2014,16(4):418.
[21]	Bhargava R, Beriwal S, McManus K, et al. CK5 is more sensitive than CK5/6 in identifying the “basal-like” phenotype of breast carcinoma[J]. Am J Clin Pathol,2008,130(5):724-730.
[22]	Horwitz KB, Dye WW, Harrell JC, et al. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts[J]. Proc Natl Acad Sci U S A,2008,105(15):5774-5779.
[23]	Kabos P, Haughian JM, Wang X, et al. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers[J]. Breast Cancer Res Treat,2011,128(1):45-55.
[24]	Hein SM, Haricharan S, Johnston AN, et al. Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress[EB/OL]. [2015-06-30]. http:/ /www. nature. com/onc/journal/vaop/ncurrent/full/onc2015206a.html.

变量	变量分类及赋值
CK5/6	阴性=1,阳性=2
Ki67	阴性=1,阳性=2
HER-2	阴性=1,阳性=2
ER	阴性=1,阳性=2
PR	阴性=1,阳性=2
E-钙黏蛋白	阴性=1,阳性=2

变量	变量分类及赋值
CK5/6	阴性=1,阳性=2
Ki67	阴性=1,阳性=2
HER-2	阴性=1,阳性=2
ER	阴性=1,阳性=2
PR	阴性=1,阳性=2
E-钙黏蛋白	阴性=1,阳性=2

临床病理特征	例数	CK5/6(例)		χ²值	P值	Ki67(例)		χ²值	P值
临床病理特征	例数	阴性	阳性	χ²值	P值	阴性	阳性	χ²值	P值
组织学分级^a
1、2级	69	55	14	0.779	0.377	27	42	2.781	0.095
3级	28	20	8	0.779	0.377	6	22	2.781	0.095
肿瘤直径^b
≤2 cm	28	23	5	0.192	0.661	11	17	0.064	0.800
＞2 cm	64	50	14	0.192	0.661	23	40	0.064	0.800
TNM分期^c
Ⅰ期+Ⅱ期	58	47	11	0.272	0.602	24	33	1.466	0.226
Ⅲ期+Ⅳ期	34	26	8	0.272	0.602	10	24	1.466	0.226
腋窝淋巴结转移
阴性	50	36	14	0.517	0.472	21	30	0.424	0.515
阳性	59	46	13	0.517	0.472	20	37	0.424	0.515

临床病理特征	例数	CK5/6(例)		χ²值	P值	Ki67(例)		χ²值	P值
临床病理特征	例数	阴性	阳性	χ²值	P值	阴性	阳性	χ²值	P值
组织学分级^a
1、2级	69	55	14	0.779	0.377	27	42	2.781	0.095
3级	28	20	8	0.779	0.377	6	22	2.781	0.095
肿瘤直径^b
≤2 cm	28	23	5	0.192	0.661	11	17	0.064	0.800
＞2 cm	64	50	14	0.192	0.661	23	40	0.064	0.800
TNM分期^c
Ⅰ期+Ⅱ期	58	47	11	0.272	0.602	24	33	1.466	0.226
Ⅲ期+Ⅳ期	34	26	8	0.272	0.602	10	24	1.466	0.226
腋窝淋巴结转移
阴性	50	36	14	0.517	0.472	21	30	0.424	0.515
阳性	59	46	13	0.517	0.472	20	37	0.424	0.515

分子指标	例数	CK5/6(例)		r值	P值	Ki67^a(例)		r值	P值
分子指标	例数	阴性	阳性	r值	P值	阴性	阳性	r值	P值
Ki67^a
阴性	41	34	7	0.128	0.186
阳性	67	48	19	0.128	0.186
ER^b
阴性	49	25	24	-0.505	＜0.001	16	32	0.076	0.440
阳性	59	56	3	-0.505	＜0.001	24	35	0.076	0.440
PR^c
阴性	71	44	27	-0.417	＜0.001	25	45	-0.046	0.627
阳性	37	37	0	-0.417	＜0.001	15	22	-0.046	0.627
HER-2
阴性	100	73	27	-0.172	0.073	40	59	0.167	0.084
阳性	9	9	0	-0.172	0.073	1	8	0.167	0.084
E-钙黏蛋白
阴性	50	32	18	-0.239	0.012	18	31	-0.023	0.813
阳性	59	50	9	-0.239	0.012	23	36	-0.023	0.813

Please choose a citation manager

Content to export